for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Infant Bacterial Therapeutics AB

IBTb.ST

Latest Trade

154.40SEK

Change

3.40(+2.25%)

Volume

5,671

Today's Range

148.00

 - 

154.60

52 Week Range

115.00

 - 

274.50

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Reg-Infant Bacterial Therapeutics Q3 Operating Loss Widens To SEK 11.0 Million

Nov 7 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::REG-INFANT BACTERIAL THERAPEUTICS AB (PUBL) INTERIM MANAGEMENT STATEMENT, JANUARY 1 – SEPTEMBER 30, 2019.Q3 OPERATING LOSS SEK 11.0 MILLION VERSUS LOSS SEK 7.7 MILLION YEAR AGO.

Infant Bacterial Therapeutics Q2 Operating Loss At SEK 8.0 Million

Aug 21 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::Q2 OPERATING LOSS SEK 8.0 MILLION VERSUS PROFIT SEK 1.3 MILLION YEAR AGO.

FDA And Infant Bacterial Therapeutics Agree On Design Of Phase III Study

May 19 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::FDA AND INFANT BACTERIAL THERAPEUTICS AGREE ON DESIGN OF PHASE III STUDY.INFANT BACTERIAL THERAPEUTICS- FDA INFORMED CO IT HAS RESPONDED SATISFACTORILY TO COMMENTS FDA HAD AND THERE ARE CURRENTLY NO ADDITIONS FROM FDA'S SIDE.INFANT BACTERIAL THERAPEUTICS- AN EVALUATION OF IBP-9414 ON DIGESTIVE SYSTEM OF PREMATURE INFANTS IN FORTHCOMING PHASE III STUDY IS NOW PLANNED.

Infant Bacterial Therapeutics Q1 Operating Loss Narrows To SEK 0.9 Mln

May 6 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::REG-INFANT BACTERIAL THERAPEUTICS AB (PUBL) INTERIM MANAGEMENT STATEMENT, JANUARY 1 – MARCH 31, 2019.JAN-MARCH OPERATING LOSS -929 KSEK (-9 144).

Infant Bacterial Therapeutics AB Announces First Distribution Agreement

March 6 (Reuters) - INFANT BACTERIAL THERAPEUTICS AB <IBTb.ST>::ANNOUNCED ON TUESDAY FIRST DISTRIBUTION AGREEMENT.SIGNED FIRST DISTRIBUTION AGREEMENT FOR IBP-9414 WITH MEGAPHARM LTD. FOR THE ISRAELI MARKET AND THE PALESTINIAN AUTHORITY'S TERRITORIES.AGREEMENT GIVES MEGAPHARM EXCLUSIVE RIGHTS TO MARKET AND SELL THE PRODUCT.MEGAPHARM TO HANDLE REGISTRATION, PRICE NEGOTIATIONS, MANAGE MARKETING AND ALL PRACTICALITIES.CO TO ESTABLISH A DISTRIBUTION AGREEMENT IN ORDER TO OBTAIN A LARGER SHARE OF FUTURE SALES REVENUE.CO'S SHARE TO ACCOUNT FOR 70 PCT OF REVENUES.

Infant Bacterial Therapeutics Q4 Operating Loss Widens To SEK 23.8 Million

Feb 8 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::Q4 OPERATING LOSS SEK 23.8 MILLION VERSUS LOSS SEK 9.1 MILLION YEAR AGO.

Infant Bacterial Therapeutics: Phase III Study Protocol Is Modified After Meeting With FDA

Nov 21 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::REG-THE PHASE III STUDY PROTOCOL IS MODIFIED AFTER IBT’S MEETING WITH THE FDA.PHASE III STUDY PROTOCOL IS MODIFIED AFTER IBT'S MEETING WITH FDA.WILL IMPROVE PROTOCOL WHICH MAY ALLOW ADDITIONAL CLAIMS SUCH AS REDUCTION IN "FEEDING INTOLERANCE".INFANT BACTERIAL THERAPEUTICS - IBT HAS CHOSEN TO MODIFY ITS PHASE III STUDY FOR PREVENTION OF NECROTIZING ENTEROCOLITIS (NEC) IN PREMATURE INFANTS.BECAUSE OF THESE CHANGES, PHASE III STUDY PROTOCOL WILL NOT START IN 2018 AS PREVIOUSLY COMMUNICATED.PHASE III STUDY PROTOCOL IS EXPECTED TO START DURING FIRST HALF OF 2019.INFANT BACTERIAL THERAPEUTICS - CO'S CURRENT FINANCIAL POSITION IS SUFFICIENT TO FINANCE IBTS CONTINUED OPERATIONS AND FINALIZE DEVELOPMENT PROGRAM.INFANT BACTERIAL THERAPEUTICS - IBT WILL IMPROVE PROTOCOL WHICH MAY ALLOW ADDITIONAL CLAIMS SUCH AS REDUCTION IN "FEEDING INTOLERANCE".

Infant Bacterial Therapeutics Q3 Operating Loss Widens To SEK 7.7 Million

Nov 14 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::JULY-SEPT OPERATING LOSS SEK 7.7 MILLION VERSUS LOSS SEK 4.6 MILLION YEAR AGO.

Infant Bacterial Therapeutics Starts Listing On Nasdaq Stockholm Main Market On Sept 10

Aug 30 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::REG-INFANT BACTERIAL THERAPEUTICS HAS BEEN APPROVED FOR LISTING ON THE MAIN MARKET OF NASDAQ STOCKHOLM.LAST DAY OF TRADING ON NASDAQ FIRST NORTH PREMIER IS SCHEDULED FOR SEPTEMBER 7, 2018.FIRST DAY OF TRADING ON NASDAQ STOCKHOLM IS SCHEDULED FOR SEPTEMBER 10, 2018.

Infant Bacterial Therapeutics AB Operating Profit at SEK 1.3 MLN

Aug 16 (Reuters) - Infant Bacterial Therapeutics AB <IBTb.ST>::Q2 NET SALES 0 KSEK (121).Q2 OPERATING PROFIT 1 286 KSEK (-13 826).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up